Future challenges

Bone Marrow Transplantation

Volumn 40, Issue 12, 2007, Pages 1157-1164

  Sirohi, B ^a   Powles, R ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Royal Marsden Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; ATIPRIMOD; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; CYCLOPHOSPHAMIDE; DEHYDRODIDEMNIN B; DEXAMETHASONE; DOXORUBICIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN HEAVY CHAIN; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; PARAPROTEIN; PERIFOSINE; PREDNISOLONE; PROTEASOME INHIBITOR; RECOMBINASE; SCIO 469; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VATALANIB; VINCRISTINE; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOLOGICAL THERAPY; BONE DESTRUCTION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOMETRY; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ELECTROPHORESIS; FINANCIAL MANAGEMENT; GENETIC ANALYSIS; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH INSURANCE; HUMAN; INDIVIDUALIZATION; KYPHOPLASTY; MEDICAL DECISION MAKING; MEDICAL SOCIETY; METHODOLOGY; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PERCUTANEOUS VERTEBROPLASTY; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; REVIEW; RISK ASSESSMENT; SEQUENCE ANALYSIS; TREATMENT PLANNING;

COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; HUMANS; MULTIPLE MYELOMA; QUALITY OF LIFE;

EID: 36649009310     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705865     Document Type: Review

References (59)

1. Sirohi B, Powles R, Mehta J, Rudin C, Kulkarni S, Horton C et al. An elective single autograft with high-dose melphalan: Single-center study of 451 patients. Bone Marrow Transplant 2005; 36: 19-24.
2. Sirohi B, Powles R. International myeloma grand round. Lancet Oncol 2001; 2: 571-579.
3. Sirohi B, Kulkarni S, Powles R. Some early phase II trials in previously untreated multiple myeloma: The royal Marsden experience. Semin Hematol 2001; 38: 209-218.
4. Powles R, Raje N, Horton C, Mehta J, Singhal S, Hickish T et al. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. Leuk Lymphoma 1996; 21: 421-427.
5. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C et al. A randomised trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results. Br J Hematol 1998; 102: 495-502.
6. Vandijken J, Kaigala GV, Lauzon J, Atrazhev A, Adamia S, Taylor BJ et al. Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts. J Mol Diagn 2007; 9: 358-367.
7. Shaughnessy JD, Haessler J, van Rhee F, Anaissie E, Pineda Roman M, Cottler-Fox M et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: Superiority of molecular genetics. Br J Haematol 2007; 137: 530-536.
8. Pilarski LM, Lauzon J, Strachan E, Adamia S, Atrazhev A, Belch AR et al. Sensitive detection using microfluidics technology of single cell PCR products from high and low abundance IgH VDJ templates in multiple myeloma. J Immunol Methods 2005; 305: 94-105.
9. Galton DA, Peto R. A progress report on the medical research council's therapeutic trial in myelomatosis. Br J Haematol 1968; 15: 319-320.
10. Sirohi B, Powles R. Multiple myeloma. Lancet 2004; 363: 875-887.
11. Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997; 97: 153-160.
12. Alexanian R, Barlogie B, Tucker S. VAD based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86-89.
13. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
14. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Eastern cooperative oncology group. Phase III clinical trial of thalidomide plus dexamethasone, compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern cooperative oncology group. J Clin Oncol 2006; 24: 431-436.
15. Baz R, Walker E, Karam MA, Choueiti TK, Jawde RA, Bruening K et al. Lenalidomide and pegytated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: Safety and efficacy. Ann Oncol 2006; 17: 1766-1771.
16. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
17. White DJ, Paul N, Macdonald DA, Meyer RM, Shepherd LE. Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: The national cancer institute of Canada clinical trials group MY.11 trial. Curr Oncol 2007; 14: 61-65.
18. Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR et al. Multiple myeloma treated with high-dose intravenous melphalan. Br J Haematol 1987; 66: 52-55.
19. Gahrton G, Tura S, Ljunginan P, Belanger C, Brandt L, Cavo M et al. Allogeneic bone marrow transplantation in multiple myeloma. European group for bone marrow transplantation. N Engl J Med 1991; 325 1267-1273.
20. Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with non-myeloablative conditioning after failed myelo-ablative hematopoietic cell transplantation. J Clin Oncol 2006; 24: 4150-4157.
21. Roussou M, Anagnostopoulos A, Kastritis E, Matsouka C, Barmparousi D, Koutsoukou V et al. Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments. Leuk Lymphoma 2007; 48: 754-758.
22. Palumbo A, Bringhen S, Caravita. T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367 825-831.
23. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575.
24. Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in mycloma. Leukemia 2006; 20: 1610-1617.
25. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ Bergsagel PL et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of Myeloma and risk-adapted therapy (mSMART): Consensus statement. Mayo Clin Proc 2007; 82: 323-341.
26. Rousselot P, Larghero J, Arnulf B, Poupon J, Royer B, Tibi A et al. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia 2004; 18: 1518-1521.
27. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz M, Greipp PR et al. In smouldering/indolent (SMM/IMM) myeloma patients treated with interleukein-1 receptor antagonist (IL-1Ra), responders demonstrate a significantly increased time to progression (TTP) and a decreased C-reactive protein (CRP) compared with nonresponders. Blood 2005; 106: 721a.
28. Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res 2006; 312: 1909-1923.
29. Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Guti-acerrez N et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781-5789.
30. Richardson P, Lonial S, Jakubowiak A, Wolf J, Krishnan A, Densmore J et al. A multicenter phase II study of perifosine (KRX-0401) alone and in combination with Dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM). Blood 2006; 108 3582a.
31. Siegel DS, Krishnan A, Lonial S, Chatta G, Alsina M, Jagannath S et al. Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM). Blood 2006; 108: 3580a.
32. Sullivan D, Singhal S, Schuster M, Berenson J, Gimsing P, Wislöff F et al. A phase II study of PXD101 in advanced multiple myeloma. Blood 2006; 108: 3583a.
33. Richardson P, Chanan-Khan AA, Lonial S, Krishnan A, Alsina M, Carroll M et al. A multicenter phase 1 clinical trial of tanespimycin (KOS-953)+bortezomib (BZ): Encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM). Blood 2006; 108: 406a.
34. Stewart KA, O'Connor OA, Alsina M, Trudel S, Urquilla PR, Vallone MK et al. Phase I evaluation of carfilzornib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses. J Clin Oncol, Proc ASCO Part I 2007; 18S: 8003a.
35. Mateos MV, Blade J, Prosper F, Lahuerta JJ, Garcia-Sanz R, Cibeira M et al. Preliminary report from an exploratory phase II trial with plitidepsin (Aplidin) in patients with refractory/relapsed multiple myeloma. Blood 2005; 106: 722a.
36. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price Troska T et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004; 103: 3271-3277.
37. Patterson J, Palombella VJ, Fritz C, Normant E. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol 2007; July 12, e-pub ahead of print.
38. Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109: 2767-2772.
39. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-3065.
40. Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007; 21: 1875-1884.
41. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 1997; 29: 1-9.
42. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-1228.
43. Lane NE, Iannini M, Atkins C, Haraoui B, Zhou L, Tsuji W et al. RANKL inhibition with denosumab decreases markers of bone and cartilage turnover in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 451a.
44. Dore R, Hurd E, Palmer W, Shergy W, Zhou L, Newmark R et al. Denosumab increases bone mineral density in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 488a.
45. The Myeolma Trialists' Collaborative Group (MTCG). Interferon as therapy for multiple myrioma: An individual patient data overview of 24 randornised trials with over 4012 patients. Br J Haematol 2001; 113: 1020-1034.
46. Sirohi B, Powles R, Lawrence D, Treleaven J, Kulkarni S, Leary A et al. An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon- {alpha}2b in patients with multiple myeloma maintained on a steady dose of interferon- {alpha}2b. Ann Oncol 2007; 18: 1388-1394.
47. Rhee F. Idiotype vaccination strategies in myeloma: How to overcome a dysfunctional immune system. Clin Cancer Res 2007; 13: 1353-1355.
48. Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in earlystage multiple myeloma patients. Clin Cancer Res 2007; 13: 1503-1510.
49. Kröger N. Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia 2007; 21: 1851-1858.
50. Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R et al. Impact of the treating institution on survival of patients with 'poor-prognosis' metastatic nonseminoma. European organization for research and treatment of cancer genitourinary tract cancer collaborative group and the medical research council testicular cancer working party. J Natl Cancer Inst 1999; 91: 839-846.
51. Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute leukaemia working party of the European group for blood and marrow transplantation. Lancet 2000; 355 1393-1398.
52. Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer 2006; 42: 1671-1683.
53. Lipscombe J, Donaldson MS, Arora NK, Brown ML, Clauser SB, Potosky AL et al. Cancer outcomes research. J Natl Cancer Inst Monogr 2004; 33: 178-197.
54. Donaldson MS. Taking stock of health related quality of life measurement in oncology practice in the United States. J Natl Cancer Inst Monogr 2004, 155-167.
55. Hussein MA. Multiple myeloma: Most common end-organ damage and management. J Natl Compr Canc Netw 2007; 5: 170-178.
56. Body JJ. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003; 97 (Suppl 3): 859-865.
57. Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. Am J Clin Oncol 2005; 28: 8-16.
58. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenbcrg D et al. Bisphosphonate-associated osteonccrosis of the Jaw: Report of a task force of the American society for bone and mineral research. J Bone Miner Res 2007; July 30, e-pub ahead of print.
59. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet 1983; 2: 822-824.